Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | GCGR | P47871 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31194856 | 0.82 | PTGS2 (0.74) | PTGS2PTGS1MAPK14MAPK13MAPK12 | |
| SCHEMBL5544695 | 0.81 | PTGS2 (0.55) | PTGS2PTGS1MAPK14NPC1RAB9A | |
| SCHEMBL5536993 | 0.80 | ALDH1A1 (0.47) | PTGS2PTGS1MAPK14NPC1RAB9A | |
| SCHEMBL15578111 | 0.80 | ACHE (0.43) | PTGS2PTGS1MAPK14NPC1RAB9A | |
| SCHEMBL18865626 | 0.80 | KDM4E (0.40) | PTGS2PTGS1MAPK14NPC1RAB9A | |
| SCHEMBL10833552 | 0.79 | PTPN1 (0.53) | MAPK14MAPK13MAPK12MAPK11ALDH1A1 | |
| SCHEMBL5214925 | 0.79 | MAPK13 (0.58) | PTGS2PTGS1MAPK14RAB9AMAPK13 | |
| SCHEMBL5541456 | 0.78 | ADORA2A (0.46) | ADORA2AADORA2BADORA1KDM4E | |
| SCHEMBL28713512 | 0.77 | APP (0.40) | PTGS2PTGS1MAPK14RAB9AMAPK13 | |
| SCHEMBL10833899 | 0.77 | MAPK13 (0.42) | PTGS2PTGS1MAPK14NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-4596816-A | Pharmaceuticals | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1986-06-24 | — | — | US | disclosed |
| EP-0092239-A2 | Oxazole derivatives, production and use thereof | Takeda Chemical Industries, Ltd. (JP) | 1983-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | PTGS2 3418/4885PTGS1 3838/4885MAPK14 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.